Skip to main navigation Skip to main content Skip to page footer

Cholangite sclérosante primitive

Informations cliniques

La cholangite sclérosante primaire (CSP) est une maladie hépatique cholestatique chronique qui entraîne une destruction progressive des voies biliaires. La prévalence de la PSC est d’environ 8 à 14 patients pour 100 000 habitants. Les hommes sont plus souvent touchés par cette maladie que les femmes (60 à 80 pour cent), et elle est plus souvent diagnostiquée entre 30 et 60 ans. La CSP est plus fréquente chez les patients atteints de maladies inflammatoires chroniques de l’intestin (85 à 90 % de la rectocolite hémorragique et 10 à 15 % de maladie de Crohn). Pour cette raison, les patients atteints de CSP présentent souvent des auto-anticorps sérologiques contre les granulocytes (pANCA), l’un des principaux antigènes étant la lactoferrine liée à l’ADN.

Diagnostic

La cholangiographie est la méthode la plus importante pour un diagnostic sûr. Bien que la CSP soit associée à de nombreux auto-anticorps, il ne s’agit pas d’une maladie auto-immune typique. Cependant, elle peut être associée à des phénomènes auto-immuns pendant l’enfance, y compris des auto-anticorps de haut titre (par exemple ANA, ANCA et ASMA). En cas de suspicion d’un syndrome de chevauchement avec une hépatite auto-immune ou une cholangite biliaire primaire (jusqu’à 10 % des cas), les tests sérologiques d’anticorps peuvent fournir des informations diagnostiques supplémentaires.

Methods
Technology Parameter Substrate Species Calibration Ig Class Format Order No.
EUROLINE EUROLINE Anti-MPO, -PR3 and -GBM (IgG)
myeloperoxidase
proteinase 3 (PR3)
glomerular basement membrane
EUROLINE IgG
IgG
16 x 01
64 x 01
DL 1200-1601-3 G
DL 1200-6401-3 G
ChLIA IDS ANCA/GBM Control Set 3 x 1.5 ml Control 1/2 human serum 2 concentrations
IS-AI17301
ChLIA IDS AMA (M2)
MIT3
antigenic coated magnetic particles MIT3 quantitative
50 x 01
IS-AI18011
ChLIA IDS Liver Control Set 3 x 1.5 ml Control 1/2 human serum 2 concentrations
IS-AI18301
IIFT antibodies against granulocyte cytoplasm,
cytoplasmic pattern (cANCA control, PR3 ab control)
IgG 05 x 02
CA 1200-0502
IIFT antibodies against granulocyte cytoplasm,
perinuclear pattern (pANCA control)
IgG 05 x 02
CA 1210-0502
IIFT antibodies against granulocyte cytoplasm, perinuclear pattern
(pANCA control, MPO ab control)
IgG 05 x 02
CA 1211-0502
IIFT cytoplasm of granulocytes (cANCA,
pANCA), nuclei of granulocytes (GS-ANA)
granulocytes,
ethanol-fixed
human IgG
IgG
IgG
IgG
10 x 05
10 x 10
180 x 10
20 x 05
10 x 05
10 x 10
20 x 05
FA 1200-1005
FA 1200-1010
FA 1200-18010
FA 1200-2005
FB 1200-1005
FB 1200-1010
FB 1200-2005
IIFT granulocytes
(cANCA, pANCA)
granulocytes,
formaldehyde-fixed
human IgG
IgG
10 x 05
10 x 10
10 x 05
10 x 10
FA 1201-1005
FA 1201-1010
FB 1201-1005
FB 1201-1010
IIFT Granulocyte Mosaic 13
cANCA, pANCA, GS-ANA
cell nuclei (ANA), cANCA, pANCA
cANCA, pANCA
3 BIOCHIPs per field:
granulocytes (EOH)
HEp-2+granulocytes (EOH)
granulocytes (HCHO)

human
human
human
IgG
IgG
IgG
IgG
IgG
IgG
10 x 05
10 x 10
10 x 50
120 x 10
20 x 05
20 x 10
10 x 05
10 x 10
10 x 50
20 x 05
20 x 10
FA 1201-1005-13
FA 1201-1010-13
FA 1201-1050-13
FA 1201-12010-13
FA 1201-2005-13
FA 1201-2010-13
FB 1201-1005-13
FB 1201-1010-13
FB 1201-1050-13
FB 1201-2005-13
FB 1201-2010-13
IIFT Granulocyte Mosaic 15
cANCA, pANCA, GS-ANA
cell nuclei (ANA), cANCA, pANCA
2 BIOCHIPs per field:
granulocytes (EOH)
HEp-2+granulocytes (EOH)

human
human
IgG
IgG
IgG
IgG
10 x 05
10 x 10
20 x 05
20 x 10
10 x 05
10 x 10
20 x 05
20 x 10
FA 1201-1005-15
FA 1201-1010-15
FA 1201-2005-15
FA 1201-2010-15
FB 1201-1005-15
FB 1201-1010-15
FB 1201-2005-15
FB 1201-2010-15
IIFT Granulocyte Mosaic 2
cANCA, pANCA, GS-ANA
cANCA, pANCA
2 BIOCHIPs per field:
granulocytes (EOH)
granulocytes (HCHO)

human
human
IgG
IgG
IgG
IgG
10 x 05
10 x 10
20 x 05
20 x 10
10 x 05
10 x 10
20 x 05
20 x 10
FA 1201-1005-2
FA 1201-1010-2
FA 1201-2005-2
FA 1201-2010-2
FB 1201-1005-2
FB 1201-1010-2
FB 1201-2005-2
FB 1201-2010-2
IIFT EUROPLUS Granulocyte Mosaic 22
cANCA, pANCA, GS-ANA
cANCA, pANCA
pANCA: myeloperoxidase (MPO)
cANCA: proteinase 3 (PR3)
4 BIOCHIPs per field:
granulocytes (EOH)
granulocytes (HCHO)
MPO BIOCHIPs
PR3 BIOCHIPs

human
human
IgG
IgG
IgG
10 x 05
10 x 10
20 x 05
10 x 05
10 x 10
FA 1201-1005-22
FA 1201-1010-22
FA 1201-2005-22
FB 1201-1005-22
FB 1201-1010-22
IIFT EUROPLUS Granulocyte Mosaic 25
cANCA, pANCA, GS-ANA
cell nuclei (ANA), cANCA, pANCA
cANCA, pANCA
glomerular basement membrane (GBM)
pANCA: myeloperoxidase (MPO)
cANCA: proteinase 3 (PR3)
6 BIOCHIPs per field:
granulocytes (EOH)
HEp-2+granulocytes (EOH)
granulocytes (HCHO)
GBM BIOCHIPs
MPO BIOCHIPs
PR3 BIOCHIPs

human
human
human
IgG
IgG
IgG
IgG
10 x 05
10 x 10
20 x 05
20 x 10
10 x 05
20 x 05
20 x 10
FA 1201-1005-25
FA 1201-1010-25
FA 1201-2005-25
FA 1201-2010-25
FB 1201-1005-25
FB 1201-2005-25
FB 1201-2010-25
IIFT EUROPLUS Granulocyte Mosaic 32
cANCA, pANCA, GS-ANA
cANCA, pANCA
cell nuclei (ANA), cANCA, pANCA
pANCA: myeloperoxidase (MPO)
cANCA: proteinase 3 (PR3)
5 BIOCHIPs per field:
granulocytes (EOH)
granulocytes (HCHO)
HEp-2+granulocytes (EOH)
MPO BIOCHIPs
PR3 BIOCHIPs

human
human
human
IgG
IgG
IgG
IgG
10 x 05
10 x 10
20 x 05
20 x 10
10 x 05
10 x 10
20 x 05
20 x 10
FA 1201-1005-32
FA 1201-1010-32
FA 1201-2005-32
FA 1201-2010-32
FB 1201-1005-32
FB 1201-1010-32
FB 1201-2005-32
FB 1201-2010-32
IIFT cytoplasm of granulocytes (cANCA,
pANCA), nuclei of granulocytes (GS-ANA)
EUROPattern
granulocytes,
ethanol-fixed
human IgG EB
IgG EB
IgG EB
IgG EB
IgG EB
10 x 05
10 x 10
120 x 10
20 x 05
20 x 10
FC 1200-1005
FC 1200-1010
FC 1200-12010
FC 1200-2005
FC 1200-2010
IIFT granulocytes
(cANCA, pANCA)
EUROPattern
granulocytes,
formaldehyde-fixed
human IgG EB
IgG EB
IgG EB
10 x 05
10 x 10
20 x 05
FC 1201-1005
FC 1201-1010
FC 1201-2005
IIFT Granulocyte Mosaic 13 EUROPattern
cANCA, pANCA, GS-ANA, EUROPattern
cell nuclei (ANA), cANCA, pANCA
cANCA, pANCA, EUROPattern
3 BIOCHIPs per field:
granulocytes (EOH)
HEp-2+granulocytes (EOH)
granulocytes (HCHO)

human
human
human
IgG EB
IgG EB
IgG EB
IgG EB
IgG EB
IgG EB
IgG EB
IgG EB
10 x 05
10 x 10
120 x 10
20 x 05
20 x 10
24 x 50
10 x 05
20 x 10
FC 1201-1005-13
FC 1201-1010-13
FC 1201-12010-13
FC 1201-2005-13
FC 1201-2010-13
FC 1201-2450-13
FW 1201-1005-13
FW 1201-2010-13
IIFT Granulocyte Mosaic 15 EUROPattern
cANCA, pANCA, GS-ANA, EUROPattern
cell nuclei (ANA), cANCA, pANCA
2 BIOCHIPs per field:
granulocytes (EOH)
HEp-2+granulocytes (EOH)

human
human
IgG EB
IgG EB
IgG EB
IgG EB
IgG EB
10 x 05
10 x 10
10 x 50
20 x 10
10 x 05
FC 1201-1005-15
FC 1201-1010-15
FC 1201-1050-15
FC 1201-2010-15
FW 1201-1005-15
IIFT Granulocyte Mosaic 2 EUROPattern
cANCA, pANCA, GS-ANA, EUROPattern
cANCA, pANCA, EUROPattern
2 BIOCHIPs per field:
granulocytes (EOH)
granulocytes (HCHO)

human
human
IgG EB
IgG EB
IgG EB
IgG EB
IgG EB
10 x 05
10 x 10
120 x 10
20 x 05
20 x 10
FC 1201-1005-2
FC 1201-1010-2
FC 1201-12010-2
FC 1201-2005-2
FC 1201-2010-2
IIFT EUROPLUS Granulocyte Mosaic 22
EUROPattern
cANCA, pANCA, GS-ANA, EUROPattern
cANCA, pANCA, EUROPattern
pANCA: myeloperoxidase (MPO), EUROPattern
cANCA: proteinase 3 (PR3), EUROPattern
4 BIOCHIPs per field:

granulocytes (EOH)
granulocytes (HCHO)
MPO BIOCHIPs
PR3 BIOCHIPs


human
human
IgG EB
IgG EB
IgG EB
10 x 05
10 x 10
20 x 10
FC 1201-1005-22
FC 1201-1010-22
FC 1201-2010-22
IIFT EUROPLUS Granulocyte Mosaic 25
EUROPattern
cANCA, pANCA, GS-ANA, EUROPattern
cell nuclei (ANA), cANCA, pANCA
cANCA, pANCA, EUROPattern
glom. basement membrane (GBM), EUROPattern
pANCA: myeloperoxidase (MPO), EUROPattern
cANCA: proteinase 3 (PR3), EUROPattern
6 BIOCHIPs per field:

granulocytes (EOH)
HEp-2+granulocytes (EOH)
granulocytes (HCHO)
GBM BIOCHIPs
MPO BIOCHIPs
PR3 BIOCHIPs


human
human
human
IgG EB
IgG EB
IgG EB
IgG EB
IgG EB
IgG EB
10 x 05
10 x 10
20 x 05
20 x 10
10 x 05
20 x 10
FC 1201-1005-25
FC 1201-1010-25
FC 1201-2005-25
FC 1201-2010-25
FW 1201-1005-25
FW 1201-2010-25
IIFT EUROPLUS Granulocyte Mosaic 32
EUROPattern
cANCA, pANCA, GS-ANA, EUROPattern
cANCA, pANCA, EUROPattern
cell nuclei (ANA), cANCA, pANCA
pANCA: myeloperoxidase (MPO), EUROPattern
cANCA: proteinase 3 (PR3), EUROPattern
5 BIOCHIPs per field:

granulocytes (EOH)
granulocytes (HCHO)
HEp-2+granulocytes (EOH)
MPO BIOCHIPs
PR3 BIOCHIPs


human
human
human
IgG EB
IgG EB
IgG EB
IgG EB
IgG EB
IgG EB
IgG EB
10 x 05
10 x 10
120 x 10
20 x 05
20 x 10
10 x 05
10 x 10
FC 1201-1005-32
FC 1201-1010-32
FC 1201-12010-32
FC 1201-2005-32
FC 1201-2010-32
FW 1201-1005-32
FW 1201-1010-32
ELISA ANCA-Profile ELISA (IgG)
(proteinase 3, MPO, elastase, cathepsin G, BPI, lactoferrin separately)
antigen-coated
microplate wells
native, human
neutrophil granulocytes
recombinant, human c-DNA
expressed in human cell line
semi-quantitative IgG 12 x 08
EA 1200-1208-1 G
ELISA Anti-PR3-hn-hr ELISA (IgG)
cANCA: proteinase 3
antigen-coated
microplate wells
hn: native, human
neutrophil granulocytes
hr: recombinant, human c-DNA
expressed in human cell line
2/20/200 RU/ml IgG 96 x 01
EA 1201-9601-2 G
ELISA Anti-MPO ELISA (IgG)
pANCA: myeloperoxidase
antigen-coated
microplate wells
native, human
neutrophil granulocytes
2/20/200 RU/ml IgG 96 x 01
EA 1211-9601 G
EUROLINE positive control serum: IgG, human, 100x concentrated
for DL 1200-X G
IgG 05 x 07
CL 1200-0507-2 G
EUROLINE EUROLINE Anti-MPO, -PR3 (IgG)
myeloperoxidase
proteinase 3
EUROLINE IgG
IgG
16 x 01
64 x 01
DL 1200-1601-2 G
DL 1200-6401-2 G
ChLIA IDS MPO antigenic coated magnetic particles MPO quantitative
50 x 01
IS-AI17011
ChLIA IDS PR3-II antigenic coated magnetic particles PR3 quantitative
50 x 01
IS-AI1702II1
ChLIA Anti-PR3 ChLIA (IgG) Antigen-coated magnetic particles quantitative IgG 100 x 1
LA 1201-10010 G
ChLIA Anti-Myeloperoxidase ChLIA (IgG) Antigen-coated magnetic particles quantitative IgG 100 x 1
LA 1211-10010 G
ChLIA Control set Anti-PR3 ChLIA (IgG) 2 x 0.4 ml control 1/2 IgG 02 x 02
LR 1201-20210 G
ChLIA Control set Anti-Myeloperoxidase ChLIA (IgG) 2 x 0.4 ml control 1/2 IgG 02 x 02
LR 1211-20210 G
* For research use only, not for in vitro diagnostic use in the sense of EU directive 98/79/EC.
1 Product manufactured by third party. Please contact your local Euroimmun representative for more information.